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(n = 17 controls), and 55 a combination with a synthetic 
progestogen (n = 34 controls), respectively. Compared to 
never MHT use, current use of ePT containing a synthetic 
progestogen for 4 or more years was associated with a sig-
nificantly increased BC risk (adjusted OR 2.07; 95 % CI 
1.26–3.39), but ePT containing micronized progesterone 
was not (adjusted OR 0.79; 95 % CI 0.37–1.71). 73 % of 
current MHT users started treatment within the first year of 
onset of menopause. early ePT (n = 52 cases and n = 38 
controls, adjusted OR 1.65; 95 % CI 1.02–2.69), but not 
early eT, starters had a significantly higher BC risk com-
pared to never MHT users. In contrast, MHT initiation 
beyond 1 year after menopause was not associated with an 
increased BC risk. The authors concluded that: (1) eT and 
ePT containing natural progesterone did not increase BC 
risk whereas, (2) BC risk was increased in users of tibo-
lone or ePT containing a synthetic progestogen, respec-
tively, and that (3) MHT use early after onset of menopause 
was associated with an increased BC risk as compared to 
women who delay MHT beyond 1 or more years.
Background
The primary indication for MHT is vasomotor symp-
tom control [2]. In women with an intact uterus systemic 
estrogens should be combined with a progestogen (natural 
progesterone or synthetic progestin) for endometrial pro-
tection. since the initial report of the women’s Health Ini-
tiative in 2002 indicating an increased BC risk associated 
with the use of conjugated equine estrogens combined with 
medroxyprogesterone acetate (MPA) [3], there is a tremen-
dous debate about whether all progestogens have the same 
negative impact on the postmenopausal mammary gland 
when combined with estrogens. Basically progestogens 
Summary
The population-based case–control study CeCILe investi-
gated the impact of various menopausal hormone therapy 
(MHT) products on breast cancer (BC) risk in 1,555 post-
menopausal women [1]. The case group (n = 739) included 
incident cases of in situ (!) or invasive BC in postmenopau-
sal women. The control group (n = 816) included women 
from the general population within predefined quotas by 
age and socio-economic status (ses). while quotas by age 
were applied to obtain similar distributions by age among 
controls and among cases, quotas by ses in control women 
were applied to reflect the distribution by ses of women 
in the general population in the study area. Data of partici-
pants were obtained by a structured questionnaire during 
in-person interviews, and from pathology reports if appli-
cable, respectively. women were divided into current and 
past MHT user. MHTs were classified in estrogen-only 
therapy (eT), estrogen combined with progestin therapy 
(ePT) and tibolone. ePT was subdivided in three subtypes 
according to the progestogen constituent: natural micro-
nized progesterone, progesterone derivatives, and testos-
terone derivatives. In comparison to never MHT users, any 
current or past MHT use (eT, ePT, tibolone) was not asso-
ciated with an increased BC risk. However, in subanalysis 
BC risk was significantly increased for current use of ePT 
for 4 or more years (n = 73 cases and n = 56 controls, 
adjusted OR 1.55; 95 % CI 1.02–2.36). within the group 
of current ePT users for 4 or more years, 14 cases had 
used estrogens combined with micronized progesterone 
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only have one effect in common, i.e., the progestogenic 
effect on the estrogen-primed endometrium [4]. Apart from 
that, there are large differences between progestogens with 
respect to other normal or malignant cells and tissues such 
as the mammary gland, respectively [5, 6]. so far there are 
four observational studies suggesting that the use of MHT 
containing progesterone or dydrogesterone, a stereoisomer 
of progesterone, is “safer” for the breast than using MHT 
containing synthetic progestins [7–10]. Of those, the pro-
spective French e3N cohort study has been the largest 
trial to address BC risk with respect to progestogen type 
in combined MHT. Compared with MHT never use, BC 
risk was increased with MHT containing “other” progesto-
gens (adjusted RR 1.69; 95 % CI 1.50–1.91) but not with 
those containing progesterone (adjusted RR 1.00; 95 % CI 
0.83–1.22) or dydrogesterone (adjusted RR 1.16; 95 % CI 
0.94–1.43), respectively [9]. similarly, a German case–con-
trol study only found an increased BC risk for use of nore-
thindrone acetate containing MHT, for more than 5 years 
but not for other progestogens [11]. Long-term randomized 
placebo-controlled trials in humans investigating the impact 
of various combined MHT on the breast are lacking. How-
ever, in non-human primates a randomized crossover trial 
in ovariectomized cynomolgus macaques was performed 
comparing the impact of estradiol (e2), e2 combined with 
progesterone, e2 combined with MPA to placebo on breast 
epithelial proliferation [12] and mammary gene expres-
sion profiles [13]. Compared to placebo, e2 combined with 
MPA resulted in significantly greater breast proliferation in 
lobular and ductal epithelium, while e2 combined with pro-
gesterone did not [12]. Gene microarray analysis resulted 
in a greater number of significantly regulated genes for e2 
combined with MPA when compared to e2 combined with 
progesterone and e2 alone with progesterone revealing 
greater antagonistic effects on e2-induced genes than MPA 
[13], which was supported by a small study in humans [14]. 
All these findings taken together suggest a more favorable 
effect for micronized progesterone and dydrogesterone on 
postmenopausal mammary gland.
Comment
The retrospective case–control study CeCILe (Loe II-
2) picks up the current exciting subject on the impact of 
progestogen type on the mammary gland. At first sight, it 
supports previous findings from the prospective e3N study 
indicating that estrogens combined with micronized pro-
gesterone are “safer” for the postmenopausal mammary 
gland. However, a closer look reveals some limitations. 
First, the statistical analysis was based on small sample 
sizes. Indeed, the primary endpoint important for power 
calculation was not given and the authors themselves 
argued that the statistical power might have been limited 
for stratified analyses. second, dosage and route of admin-
istration of progesterone were not assessed which might 
have an impact of BC incidence [6]. Next, cases included 
in situ and invasive BC, and the authors did not present the 
respective absolute numbers. However, ductal carcinoma 
in situ (DCIs) is a non-obligate precursor of invasive BC 
with “only” 40 % of these lesions progressing to invasive 
disease if untreated [15]. Therefore, the analysis should 
have been stratified with respect to in situ and invasive BC, 
respectively. Finally, there is a potential confounding by 
ses since control selection was based on ses within the 
population of the study area and not on BC cases.
Taken together the CeCILe study serves as another hint 
indicating a favorable mammary profile for MHT contain-
ing progesterone. However, more evidence is needed. In 
respect to tibolone, the authors surprisingly commented 
on their results that “tibolone was also associated with an 
increased risk of BC” contradicting the endocrine socie-
ty’s statement that “tibolone reduces the risk of developing 
BC (LoeB)” [16]. In fact, absolute numbers for any dura-
tion of current (n = 17 cases, n = 8 controls) and past tibo-
lone users (n = 10 cases, n = 15 controls) were very small. 
statistical analysis did not reach significance at any time. 
Thus, interpretation should be more softened. Interestingly, 
the time gap between menopause and MHT initiation mat-
tered which supports previous observations that delaying 
MHT onset for a certain, but yet undefined interval seems 
to be beneficial for the postmenopausal breast [17–19] 
which needs further investigation.
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